Leap Therapeutics (LPTX) Competitors

Precision BioSciences (NASDAQ:DTIL) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Which has more risk & volatility, DTIL or LPTX?

Precision BioSciences has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500.

Which has stronger valuation & earnings, DTIL or LPTX?

Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$68.70M	0.80	$7.17M	-$8.81	-0.53
Leap Therapeutics	N/A	N/A	-$67.56M	-$1.70	-0.20

Do analysts rate DTIL or LPTX?

Precision BioSciences currently has a consensus price target of $47.00, indicating a potential upside of 902.13%. Leap Therapeutics has a consensus price target of $3.38, indicating a potential upside of 895.58%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Precision BioSciences is more favorable than Leap Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Leap Therapeutics	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media prefer DTIL or LPTX?

In the previous week, Precision BioSciences had 3 more articles in the media than Leap Therapeutics. MarketBeat recorded 5 mentions for Precision BioSciences and 2 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.93 beat Precision BioSciences' score of -0.09 indicating that Leap Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Leap Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in DTIL or LPTX?

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 4.5% of Precision BioSciences shares are held by insiders. Comparatively, 7.5% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is DTIL or LPTX more profitable?

Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Leap Therapeutics' return on equity of -162.15% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-6,205.79%	-176.47%	-69.05%
Leap Therapeutics	N/A	-162.15%	-120.05%

Summary

Precision BioSciences beats Leap Therapeutics on 9 of the 15 factors compared between the two stocks.